Trial Profile
A multicenter randomized Phase III trial of enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Abiraterone; Prednisolone
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms EN-AB-LE Study for PCa; ENABLE
- 27 Jan 2024 Results of Sub-analysis analyzing the efficacy of modified dose in ENABLE study castration-resistant prostate cancer presented at the 2024 Genitourinary Cancers Symposium
- 19 Feb 2022 Results (n=203) presented at the 2022 Genitourinary Cancers Symposium
- 17 Nov 2021 Status changed from recruiting to active, no longer recruiting.